secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cocrystal Pharma, Inc. (COCP)
CIK:        0001412486
Form:       8-K
Filed at:   2025-06-05T23:59:59+00:00
Accession:  0001641172-25-013776
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cocrystal Pharma's norovirus antiviral CDI-988 to be presented at MHSRS in August 2025
--------------------------------------------------------------------------------

- CDI-988, a broad-spectrum protease inhibitor, will be featured in an oral presentation at the 2025 Military Health System Research Symposium on August 4, 2025 in Kissimmee, Florida.
- Cocrystal is developing CDI-988 as a norovirus prophylaxis and treatment; no approved antivirals or vaccines for norovirus currently exist.
- President and co-CEO Sam Lee, PhD, will discuss Phase 1 safety, tolerability, and pharmacokinetics results at the conference.
- CDI-988 targets a highly conserved region in 3CL viral proteases, potentially halting infection early regardless of viral strain or mutation.
- Norovirus spreads rapidly in confined spaces like military settings, posing a threat to operational effectiveness and economic burden.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1412486/000164117225013776/0001641172-25-013776-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1412486/000164117225013776/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-013776

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer